VacZine Analytics  
MarketVIEW: Herpes Zoster (adult) vaccines

Published: Oct 2014

Varicella-zoster virus is a ubiquitous human alphaherpesvirus, which after infection in childhood causes a relatively mild self-limiting illness. However, if the virus becomes reactivated later on in life it can cause a painful rash (shingles), often leading to postherpetic neuralgia (PHN). PHN has a significant economic burden because patients require systemic anti-viral therapy and pain management.

This MarketVIEW product is a comprehensive commercial opportunity assessment detailing the potential market for Herpes Zoster vaccines (doses 000s, $ 000s) to 2030 across Western + LATAM markets. The forecast takes into account the possible introduction of new, improved Zoster vaccines from GSK Biologicals and Merck & Co and discusses their potential impact in terms of cost effectiveness and willingness of new countries to adopt national immunisation programs. Two forecast scenarios are included LOW and HI along with up-to-date discussion of disease dynamics, epidemiology and current research and development status.

THIS PRODUCT IS A SUMMARY PRESENTATION + 2 MODELS

To order please contact your region account manager, buy "on-line" or order direct at: orders@vaczine-analytics.com

CAT No: CONTENTS: PURCHASE:
VAMV054 Click here>>
Choose option:
*Prices quotes are for 1 region license only. Regions are North America, or EU or ROW. For UK orders VAT will be added at 20%. Please review the TERMS and CONDITIONS of purchase.

Return to main list>> Questions about this report?






© 2014 VacZine Analytics. All rights reserved. Disclaimer | Privacy | Terms and conditions. hosted by chillydomains